Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for Chronic Obstructive Pulmonary Disease Management
The objectives of this study are:
1) To develop blood biomarkers that can diagnose AECOPD.
2) To develop blood biomarkers that can prognose AECOPD.
To meet the study objectives, discovery and replication of biomarkers will be conducted on the existing cohorts from the following studies described above: ECLIPSE, STATCOPE, MACRO, CanCOLD, TNF-alpha, CARTaGENE, and LEUKO. In addition, samples from patients enrolled through the Rapid Transition Program at St. Paul's Hospital (SPH) and Vancouver General Hospital (VGH) will be used for diagnostic biomarker discovery and replication and prognostic biomarker replication.
New biomarker blood tests can be used to better identify and manage patients with COPD and those who are at higher risk of AECOPD. The prognostic blood test will empower clinicians to aggressively treat high risk patients with preventive therapies (including inhaled corticosteroids) for exacerbation, while implementing a more conservative approach for low risk patients (i.e., treat with only bronchodilators). A diagnostic blood test will enable clinicians to accurately diagnose AECOPD during the crescendo phase of the event and implement anti-exacerbation therapies that can reduce the severity of symptoms and abort full blown attacks that lead to ER visits and hospitalizations. The tests have the potential to reduce the growing health and financial burden of COPD in Canada.